Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 279 recruiting now early-phase tilt #6 of 28,963 conditions

Cancer: early-phase trial registry

279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #6 of 28,963 conditions by registered trial count.

621 US clinical trials · 279 currently recruiting · #6 of 28,963 conditions by registered trial count

Cancer: 621 US clinical trials tracked, 279 recruiting.

Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.

Open enrollment, early-phase tilt

Cancer has 621 registered US clinical trials, 279 of them open to new participants right now, about 45% of the total.

279
recruiting participants now
45%
of trials open to enrollment
31
in Phase 3-4 (later-stage)
31
top sponsor: M.D. Anderson Cancer Center

Corpus placement: #6 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Cancer is recruiting above its size-band peers.

    279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cancer trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cancer enrolment sits around 108 participants.

    Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.

  4. Cancer research is mostly interventional.

    462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1116Phase 248Phase 327Phase 44

Open and recent trials

621 total, page 8 of 13

ACTIVE NOT RECRUITING NA 44 participants

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

University of California, San Francisco

NCT03739372

ACTIVE NOT RECRUITING 43 participants

Assessment of Paclitaxel-Induced Neuropathy

University of Chicago

NCT01953159

ACTIVE NOT RECRUITING Phase 1 42 participants

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

HUYABIO International

NCT05163028

ACTIVE NOT RECRUITING Phase 1 39 participants

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

NCT05704985

ACTIVE NOT RECRUITING NA 38 participants

Researching the Effect of Aerobic Exercise on Cancer

Memorial Sloan Kettering Cancer Center

NCT03996239

ACTIVE NOT RECRUITING NA 36 participants

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

Boston Scientific Corporation

NCT06192758

ACTIVE NOT RECRUITING NA 35 participants

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

M.D. Anderson Cancer Center

NCT05124405

ACTIVE NOT RECRUITING NA 34 participants

Ovarian Reserve Testing in Female Young Adult Cancer Survivors

University of California, San Diego

NCT01421095

ACTIVE NOT RECRUITING NA 33 participants

Expanding Rural Health Cancer Control Capacity

Debra Friedman

NCT04765072

ACTIVE NOT RECRUITING NA 31 participants

Implementation of a Health System Intervention to Improve Quality of Cancer Care for Rural Patients

Mary Charlton

NCT05645328

ACTIVE NOT RECRUITING NA 30 participants

ACT-Together (Acting on Cancer Testing-Together)

M.D. Anderson Cancer Center

NCT06549153

ACTIVE NOT RECRUITING NA 28 participants

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

UNC Lineberger Comprehensive Cancer Center

NCT05823740

ACTIVE NOT RECRUITING Phase 2 27 participants

Split-Dose R-CHOP for Older Adults With DLBCL

University of Wisconsin, Madison

NCT03943901

ACTIVE NOT RECRUITING Phase 2 23 participants

Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

Adam Burgoyne, MD, PhD

NCT03556384

ACTIVE NOT RECRUITING 21 participants

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

St. Jude Children's Research Hospital

NCT05164016

ACTIVE NOT RECRUITING NA 20 participants

Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

University of California, Irvine

NCT06340906

ACTIVE NOT RECRUITING NA 19 participants

Virtual Exercise Program to Reduce Cancer Related Fatigue

University of Colorado, Denver

NCT04533165

ACTIVE NOT RECRUITING NA 9 participants

Exercise Rehabilitation in Veteran Cancer Survivors

VA Office of Research and Development

NCT03621813

ACTIVE NOT RECRUITING Phase 2 4 participants

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

M.D. Anderson Cancer Center

NCT06754501

COMPLETED 139,692 participants

Development of Computer-aided Detection and Diagnosis From Imaging Techniques

National Institutes of Health Clinical Center (CC)

NCT00057252

COMPLETED 8,038 participants

Development and Validation of Harbinger Health Test for Early Cancer Detection

Harbinger Health

NCT05435066

COMPLETED 7,435 participants

The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

Freenome Holdings

NCT05254834

COMPLETED Phase 1 7,192 participants

Cooking for Health Optimization With Patients

Tulane University

NCT03443635

COMPLETED 6,300 participants

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

National Eye Institute (NEI)

NCT00116090

COMPLETED 5,451 participants

Epidemiology of Venous Thromboembolism

Brigham and Women's Hospital

NCT00456196

COMPLETED NA 4,104 participants

Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center

Northwestern University

NCT03988543

COMPLETED 3,955 participants

Community Cancer Centers Pilot Patient Survey

National Cancer Institute (NCI)

NCT00786656

COMPLETED Phase 3 3,212 participants

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Sanofi

NCT00694382

COMPLETED NA 3,002 participants

The Genetic Information and Family Testing (GIFT) Study

University of Michigan Rogel Cancer Center

NCT05552664

COMPLETED 1,803 participants

Pesticides--Health Fertility and Reproductive Risk

National Institute of Environmental Health Sciences (NIEHS)

NCT00015561

COMPLETED Phase 3 1,538 participants

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Novartis Pharmaceuticals

NCT01235962

COMPLETED 1,400 participants

Concordance Between ctDNA Assay and FoundationOne

Foundation Medicine

NCT02620527

COMPLETED Phase 3 1,221 participants

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

R-Pharm

NCT00082433

COMPLETED Phase 3 1,046 participants

Cancer Venous Thromboembolism (VTE)

Daiichi Sankyo

NCT02073682

COMPLETED NA 994 participants

Serious Illness Communication Project

Dana-Farber Cancer Institute

NCT01786811

COMPLETED NA 811 participants

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Alliance Foundation Trials

NCT02744092

COMPLETED 800 participants

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

Nucleix

NCT04264767

COMPLETED NA 749 participants

Genetic Testing in Young Adults With Cancer Study

University of Pennsylvania

NCT04533555

COMPLETED Phase 2 730 participants

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Exelixis

NCT00940225

COMPLETED 694 participants

Ezra Faster Scan Study

Ezra AI

NCT05385718

COMPLETED NA 685 participants

Improving Tobacco Treatment Rates for Cancer Patients Who Smoke

Abramson Cancer Center at Penn Medicine

NCT04738643

COMPLETED NA 672 participants

Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial

University of Pittsburgh

NCT03824158

COMPLETED NA 650 participants

Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

Kaiser Permanente

NCT04351880

COMPLETED NA 645 participants

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

University of North Carolina, Chapel Hill

NCT01969370

COMPLETED Phase 2 600 participants

Promoting Healthy Lifestyles Among Firefighters

Oregon Health and Science University

NCT00006181

COMPLETED NA 550 participants

Multidisciplinary Inpatient Palliative Care Intervention

Kaiser Permanente

NCT00325611

COMPLETED 506 participants

Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers

University of California, San Diego

NCT02534675

COMPLETED NA 500 participants

Effective Communication for Preventing and Responding to Oncology Adverse Events

University of Massachusetts, Worcester

NCT01871948

COMPLETED NA 498 participants

Post-chemotherapy Symptom Management SMART

University of Arizona

NCT03494166

COMPLETED NA 489 participants

ACCESS (Access for Cancer Caregivers for Education and Support for Shared Decision Making)

Washington University School of Medicine

NCT02929108

← Previous Page 8 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 116
Phase 2 48
Phase 3 27
Phase 4 4

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Cancer right now

279 recruiting of 621 indexed (45% open).

Phase mix: 31 late (III/IV) vs 164 early (I/II) (early-phase heavy).

Top sponsor: M.D. Anderson Cancer Center (31 trials), 9 others listed. 50 shown below, recruiting first. #6 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Cancer?

PlainTrial tracks 621 US clinical trials for Cancer, of which 279 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.